in

American biotechnology leader: Gilead Sciences (GILD) (1987)

Gilead Sciences, Inc. (NASDAQ:GILD) was founded in 1987 and is headquartered in Foster City, California (Foster City), with 11,800 full-time employees. It is a world-leading biopharmaceutical company in the United States, Discovery, development and commercialization of therapies and drugs in areas of unmet medical needs in Europe and internationally.

Gilead Sciences

Gilead Sciences (GILD):

The drugs developed and sold by Gilead Sciences are widely used in the treatment of viral infections, including viral infections, fungal infections and bacterial infections. The company also pays special attention to the treatment of cancer, AIDS, and hepatitis C.

Gilead Sciences has specialized liposomal drug treatment technology, the use of which makes drugs safer, simpler and more effective for patients.Gilead owns Tamiflu’s patent rights from 1996 to 2016. In addition to the United States, Gilead Sciences’ products are also exported to Canada, Australia, New Zealand, Germany, the United Kingdom, France, Italy, Spain, Greece, Ireland, Portugal and other countries ( Merck ’s only approved drug in China has arrived. It will be off the shelf during the period and is not currently sold in China).

Gilead Sciences, Inc. has signed cooperation agreements with Bristol-Myers Squibb Company , Janssen Sciences Ireland UC, Japan Tobacco Inc. and Galapagos NV.

Gilead Sciences’ products include :

  • Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta are used for the treatment of adult human immunodeficiency virus (HIV) infection;
  • Harvoni, Sovaldi, Viread and Hepsera products for the treatment of liver diseases;
  • Zydelig, a PI3Kδ inhibitor combined with rituximab, is used in the treatment of certain blood cancers;
  • Letairis, an endothelin receptor antagonist for the treatment of pulmonary hypertension;
  • Ranexa, a pill for the treatment of chronic angina pectoris;
  • Lexiscan / Rapiscan injection is used as a pharmacological stress agent for radionuclide myocardial perfusion imaging;
  • Cayston, an antibiotic used to treat the respiratory system of patients with cystic fibrosis;
  • Tamiflu, an oral antiviral drug capsule used to treat and prevent influenza A and B;
  • AmBisome, an antifungal agent to treat severe invasive fungal infections;
  • macugen drug, an anti-angiogenic oligonucleotide used to treat neovascularization and age-related macular degeneration.

In addition, Gilead Sciences has candidate products (clinical stage) developed in various stages for HIV/AIDS and liver diseases such as hepatitis B virus and hepatitis C virus treatment, inflammation/tumor, severe cardiovascular and respiratory diseases, and Diabetic nephropathy and Ebola virus.

The two hepatitis C star drugs Sovaldi and Harvoni launched by Gilead have a cure rate of 90%.

All Gilead products (details):

Gilead Sciences Product portfolio

Click to see larger picture

Gilead Sciences sells its products through its commercial team and/or with third-party distributors and corporate partners.

Gilead’s financial data:

Currency unit: million dollars

Stock price unit: USD

years

income

Net profit

Total assets

share price

Number of employees

2005

2,028

814

3,766

9.77

2006

3,026

−1,190

4,086

14.31

2007

4,230

1,585

5,835

18.30

2008

5,336

1,979

6,937

22.74

2009

7,011

2,636

9,699

21.32

2010

7,949

2,901

11,593

18.15

2011

8,385

2,804

17,303

18.46

2012

9,702

2,592

21,240

26.13

2013

11,202

3,075

22,579

51.83

6,000

2014

24,890

12,101

34,664

82.82

7,000

2015

32,639

18,108

51,716

98.83

8,000

2016

30,390

13,501

56,977

78.87

9,000

2017

26,107

4,628

70,283

70.13

10,000

2018

22,127

5,455

63,675

63.86

11,000

2019

22,449

5,386

61,627

11,800

Gilead Sciences (GILD) History:

Gilead Sciences, Inc. (Gilead Sciences, Inc.) is a large American biopharmaceutical company that mainly produces and develops drugs for AIDS, hepatitis B, hepatitis A and various infectious diseases.

The company was founded in June 1987 by doctor Michael L. Riordan. Riverdan studied at the University of Washington, Johns Hopkins University School of Medicine, and Harvard Business School. He was 29 when he founded the company. In the early days, it received a US$2 million investment from the venture capital firm Menlo Ventures. The chairman of Gilead Sciences was held by Menlo Ventures. In 1993, Ruivoldan became the chairman. The company was listed on the Nasdaq in January 1992. Donald Rumsfeld became chairman of the board in January 1997, but he resigned as the Secretary of Defense in 2001. In 2002, the company began to transform to specialize in antiviral drugs and sold its anticancer drug business to OSI Pharmaceuticals for 200 million US dollars. In October of the same year, it was decided to acquire Triangle Pharmaceutical for USD 464 million. Later, after a series of mergers (see the list below), the current scale was formed.

  • In June 1987, Michael L. Riordan founded Gilead Sciences;
  • In 1990, signed a research agreement with GlaxoSmithKline to research and develop genetic code blockers (antisense). The cooperation was terminated in 1998. Gilead Sciences sold the antisense intellectual property portfolio to Isis Pharmaceuticals ;
  • In January 1992, Gilead Sciences IPO was listed on Nasdaq;
  • In March 1999, Gilead Sciences acquired NeXstar Pharmaceuticals;
  • In 2002, Gilead started the company’s transformation to specialize in antiviral drugs, selling its anticancer drug business to OSI Pharmaceuticals at a price of 200 million US dollars;
  • In October 2002, Gilead Sciences decided to acquire Triangle Pharmaceuticals for US$464 million;
  • In January 2003, Gilead Sciences completed the acquisition of Triangle Pharmaceuticals;
  • In 2006, Gilead Sciences acquired Corus Pharma, Inc. for US$365 million;
  • In November 2006, Gilead Sciences acquired Raylo Chemicals, Inc. for USD 133.3 million;
  • In December 2006, Gilead Sciences acquired Myogen, Inc. for US$2.5 billion;
  • In 2009, Gilead Sciences acquired CV Therapeutics, Inc. for 1.4 billion US dollars;
  • In 2010, Gilead Sciences acquired CGI Pharmaceuticals for US$120 million;
  • In 2010, Gilead Sciences acquired Arresto Biosciences, Inc. for US$225 million;
  • In 2011, Gilead Sciences acquired Calistoga Pharmaceuticals for US$375 million;
  • In 2011, Gilead Sciences acquired Pharmasset, Inc. for $10.4 billion (the company’s largest acquisition);
  • On July 16, 2012, the FDA approved Gilead’s Truvada, the first drug to reduce the risk of HIV infection;
  • In 2013, Gilead Sciences acquired YM Biosciences, Inc. for US$510 million;
  • In 2015, Gilead Sciences acquired Phenex Pharmaceuticals for US$470 million;
  • In 2015, Gilead Sciences acquired EpiTherapeutics for US$65 million;
  • In 2015, Gilead Sciences acquired a 15% stake in Galapagos NV for US$425 million;
  • In 2016, Gilead Sciences acquired Nimbus Apollo, Inc. for US$400 million;
  • On August 28, 2017, Gilead Sciences acquired Kite Pharma for US$11.9 billion ;
  • In 2017, Gilead Sciences acquired Cell Design Labs for US$567 million;
  • On May 9, 2019, the U.S. Department of Health and Human Services (HHS) announced that Gilead Sciences will donate free drugs to Truvada. The drug is the only drug approved for the prevention of HIV infection. It will provide 200,000 free drugs per year for 11 years. Donated by patients;
  • In March 2020, Gilead Sciences announced that it would acquire Forty Seven Inc. for $95.50 per share ($4.9 billion in total). The transaction was completed on April 17 of the same year;
  • 2020 June, Bloomberg (Bloomberg) reported that AstraZeneca (AstraZeneca Plc) has been with Gilead (Gilead) the initial contact, to seek potential merger transactions worth nearly $ 240 billion;
  • In June 2020, Gilead Sciences announced that it would acquire a 49.9% stake in the privately held Pionyr Immunotherapeutics Inc. for US$275 million;
  • On September 14, 2020, Gilead Sciences (Inc.) announced that it had reached a deal to acquire Immunomedics Inc. for US$21 billion .

Gilead Sciences Acquisations

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all Intels

Personal medical insurance plan company: Benefytt Technologies, Inc. (BFYT)

Extreme sports camera manufacturer: GoPro (GPRO) (2004)